DOP011: Early immunomodulator exposure and the long-term outcome of Crohn’s disease: target for changing the natural history?ECCO'16 DOP 2016
1
DOP012: Do ulcerative colitis patients treated withcorticosteroids at diagnosis really have a more aggressive disease course?ECCO'16 DOP 2016
1
DOP013: A 104 week mucosal healing assessment of symptomatic small bowel Crohn’s diseaseECCO'16 DOP 2016
1
DOP014: Nutritional optimisation of pre-surgical Crohn’s disease patients with enteral nutrition significantly decreases length of stay and need for a stomaECCO'16 DOP 2016
1
DOP015: Myenteric plexitis is a risk factor for endoscopic and clinical postoperative recurrence after ileocolonic resection in Crohn’s diseaseECCO'16 DOP 2016
1
DOP017: Colectomy Free Survival is Independent of Initial Infliximab Dosing Strategy in Hospitalised Ulcerative Colitis PatientsECCO'16 DOP 2016
1
DOP019: Efficacy of Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's DiseaseECCO'16 DOP 2016
1
DOP022: Targeting Immune Cell Metabolism: LYC-30937, A Novel Therapeutic Approach for Inflammatory Bowel DiseaseECCO'16 DOP 2016
1
DOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseasesECCO'16 DOP 2016
1
DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitisECCO'16 DOP 2016
1
DOP027: Large scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapyECCO'16 DOP 2016
1
DOP028: Efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohortECCO'16 DOP 2016
1